Lilly Completes Acquisition of Versanis Bio
Eli Lilly and Company announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab,…
Read More...
Read More...